Uptrend on the daily chart: above its 50- and 200-day averages · 50-day below the 200-day · SuperTrend up · inside the Ichimoku cloud · RSI 0 (oversold) · MACD above its signal · at its 52-week high
None of the 29 investors followed here reported a position in VIVXF in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a VIVXF trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for VIVXF.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% | ||
| 2025 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% |
| 2024 | 591.7 | -59.0 | 61.8 | 132.7 | -81.2 | 200.0 | 0.0 | 0.0 | -97.2 | 0.0 | 0.0 | 0.0 | −83.3% |
| 2023 | 43.5 | -44.6 | -33.3 | -34.6 | -55.8 | 25.0 | -3.5 | -25.2 | -44.6 | 19.6 | -49.1 | -78.6 | −99.0% |
| 2022 | 0.9 | -24.3 | -15.0 | -0.7 | 3.7 | -3.5 | -9.3 | -7.5 | -2.7 | -16.6 | -38.0 | -5.2 | −74.2% |
| 2021 | -6.0 | 7.6 | -17.2 | 7.8 | -11.5 | -8.8 | -11.0 | -13.3 | 14.1 | -2.1 | -1.8 | -21.0 | −51.2% |
| 2020 | 15.6 | -6.8 | -3.2 | -2.2 | -2.0 | -23.0 | -4.9 | 13.2 | 11.3 | -9.2 | 12.3 | 17.7 | +10.6% |
| 2019 | 23.6 | 50.0 | -2.0 | -2.2 | -21.5 | 20.5 | -11.5 | -2.9 | -3.6 | -29.0 | 22.2 | 9.8 | +32.6% |
| 2018 | 4.4 | -7.6 | -0.9 | -6.9 | 0.0 | -24.7 | 0.0 | -17.1 | -3.6 | 31.1 | -31.2 | -9.4 | −56.2% |
| 2017 | 6.4 | -11.6 | 0.0 | 0.5 | -12.2 | 21.2 | -10.1 | 6.0 | -6.3 | -3.2 | -9.1 | 0.0 | −21.0% |
| 2016 | -29.1 | 0.0 | 0.0 | 94.4 | -21.4 | 21.8 | 49.3 | 2.4 | 1.3 | 44.6 | -25.3 | -16.1 | +85.0% |
| 2015 | -3.0 | -1.6 | 19.0 | -16.0 | 14.3 | 0.0 | 0.0 | -34.7 | 6.4 | 0.0 | 1.6 | 0.0 | −23.0% |
| 2014 | 0.0 | -29.9 | 7.1 | -6.6 | 0.0 | 0.0 | 0.0 | 0.0 | -11.1 | -11.8 | 28.0 | 3.1 | −27.5% |
| 2013 | 4.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | +4.6% |
No analyst coverage for this instrument.
Avivagen Inc. focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. The company offers OxC-beta Livestock, a premix for inclusion in livestock feeds; Vivamune health chews for dogs; Dr. Tobias dog chews; and Dr. Tobias Beta blend for the human immune system. It serves in the United States, Mexico, Philippines, Taiwan, New Zealand, Thailand, Australia, and Malaysia. The company is headquartered in Ottawa, Canada.
No recent headlines.